Graham Camilla 4
4 · Summit Therapeutics Inc. · Filed Oct 7, 2020
Insider Transaction Report
Form 4
Graham Camilla
Chief Clinical Affairs Officer
Transactions
- Award
Stock Option (right to buy)
2020-10-04$3.34/sh+400,000$1,336,000→ 400,000 totalExercise: $3.34Exp: 2030-10-04→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets.